In ₹ Crore except Per Share Latest Annual | SHUKRAPHAR FY24 | BPLPHARMA FY23 | JENBURPH FY26 | KPL FY24 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 2.35× | 37.02× | — | — | 37.02× -94% | |
| Growth | ||||||
| Revenue CAGR 3Y | — | — | 7.26% | — | 7.26% | |
| Revenue CAGR 5Y | — | — | 9.07% | — | 9.07% | |
| Net Income CAGR 3Y | — | — | 12.18% | — | 12.18% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 26.02% | 9.80% | 23.81% | 21.69% | 21.69% +20% | |
| Net Income Margin | ◆ 24.86% | 11.16% | 20.59% | — | 15.88% +57% | |
| Return on Common Equity | ◆ 32.16% | 12.74% | — | — | 12.74% +152% | |
| Return on Capital Employed | — | — | — | 19.18% | 19.18% | |
| Return on Assets | ◆ 23.82% | 7.90% | 15.37% | — | 11.63% +105% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.05× | ◆ 0.04× | — | 0.43× | 0.23× -79% | |
| Interest Coverage | ◆ 60.89× | 7.10× | — | 4.54× | 5.82× +946% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹74.6 Cr | ₹218 Cr | ₹169 Cr | ₹307 Cr | ₹218 Cr -66% | |
| Net Income | ₹18.5 Cr | ₹24.3 Cr | ₹34.7 Cr | — | ₹29.5 Cr -37% | |
| Total Assets | ₹77.8 Cr | ₹308 Cr | ₹226 Cr | ₹398 Cr | ₹308 Cr -75% | |
| EPS | ₹23 | ₹42.14 | — | — | ₹42.14 -45% | |